GLP-1 agonists reduce appetite, modulate satiety circuits, alter hepatic lipid handling, improve endothelial function, attenuate inflammatory tone, influence microglial behavior, and appear to exert downstream neuroprotective effects, yet the field cannot convincingly articulate how these effects relate to one another, which are primary versus secondary, or which are merely correlative epiphenomena arising from broader systemic shifts
Neuronal GLP1R mediates liraglutide's anorectic but not glucoselowering effect
NON-SURGICAL FAT REDUCTION Belly fat is a common complaint for many and despite leading an otherwise healthy lifestyle, many feel it is a tricky area to reduce fat from with diet and exercise alone
We hypothesize that GLP1-RAs may modulate SARSCoV-2 activity
Because its designed with GLP-1 users in mind, it contains nutrients that may be difficult to get enough of with a significantly reduced appetite
The "L" stands for the "left-handed" orientation of the amino acids that make up the peptide
